📊 CVKD Key Takeaways
Investment Thesis
Cadrenal Therapeutics is a pre-revenue clinical-stage pharmaceutical company with severe negative fundamentals and rapidly depleting cash resources. The company is burning approximately $10M annually with no revenue generation and only ~13 months of cash runway remaining, making near-term capital raise or partnership critical for survival.
CVKD Strengths
- Adequate short-term liquidity with $3.9M cash representing 95% of total assets
- Low debt burden with zero long-term debt and minimal leverage
- Maintains current ratio of 3.02x, indicating ability to cover short-term obligations
CVKD Risks
- Zero revenue with no clear commercialization timeline for pipeline assets
- Negative operating cash flow of -$10.0M annually indicates unsustainable burn rate
- Severely negative ROE (-372.9%) and ROA (-249.5%) reflect value destruction
- Cash runway of approximately 13 months at current burn rate creates existential liquidity risk
- EPS of -$5.23 on minimal equity base demonstrates pre-commercial stage weakness
- Single Form 4 insider filing in last 90 days suggests minimal insider investment confidence
Key Metrics to Watch
- Operating cash flow trend and monthly burn rate trajectory
- Time-to-cash-depletion and capital raise announcements
- Clinical trial progress, regulatory approvals, and partnership developments
- Cash balance changes and dilution from future financing activities
- Any revenue generation milestones or commercialization progress
CVKD Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 3.02x current ratio provides a solid financial cushion.
CVKD Profitability Ratios
CVKD vs Healthcare Sector
How Cadrenal Therapeutics, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
CVKD Balance Sheet & Liquidity
CVKD 5-Year Financial Trend
5-Year Trend Summary: Cadrenal Therapeutics, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-9.29 indicates the company is currently unprofitable.
CVKD Growth Metrics (YoY)
CVKD Capital Allocation
CVKD SEC Filings
Access official SEC EDGAR filings for Cadrenal Therapeutics, Inc. (CIK: 0001937993)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CVKD
What is the AI rating for CVKD?
Cadrenal Therapeutics, Inc. (CVKD) has an AI rating of STRONG SELL with 95% confidence, based on fundamental analysis of SEC EDGAR filings.
What are CVKD's key strengths?
Adequate short-term liquidity with $3.9M cash representing 95% of total assets. Low debt burden with zero long-term debt and minimal leverage.
What are the risks of investing in CVKD?
Zero revenue with no clear commercialization timeline for pipeline assets. Negative operating cash flow of -$10.0M annually indicates unsustainable burn rate.
What is CVKD's revenue and growth?
Cadrenal Therapeutics, Inc. reported revenue of N/A.
Does CVKD pay dividends?
Cadrenal Therapeutics, Inc. does not currently pay dividends.
Where can I find CVKD SEC filings?
Official SEC filings for Cadrenal Therapeutics, Inc. (CIK: 0001937993) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CVKD's EPS?
Cadrenal Therapeutics, Inc. has a diluted EPS of $-5.23.
How is the AI analysis conducted?
Our AI (Claude) analyzes publicly available SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports to evaluate financial health, profitability ratios, balance sheet strength, and growth metrics.